Pharmathene, Inc. (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.
Industry, Sector and Symbol:
- Sector: Finance
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSE:PIP
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $0.77
- 200 Day Moving Avg: $2.08
- 52 Week Range: $0.47 - $3.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.29
- P/E Growth: 0.00
- Average Volume: 4.43 million shs.
Frequently Asked Questions for PharmAthene (NYSE:PIP)
What is PharmAthene's stock symbol?
PharmAthene trades on the New York Stock Exchange (NYSE) under the ticker symbol "PIP."
How often does PharmAthene pay dividends? What is the dividend yield for PharmAthene?
PharmAthene announced a special dividend on Monday, November 21st. Investors of record on Sunday, January 24th will be given a dividend of $2.91 per share on Friday, February 3rd. The ex-dividend date of this dividend is Monday, February 6th. View PharmAthene's Dividend History.
How were PharmAthene's earnings last quarter?
PharmAthene, Inc. (NYSE:PIP) announced its quarterly earnings data on Monday, March, 9th. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The firm had revenue of $1.83 million for the quarter. View PharmAthene's Earnings History.
Are investors shorting PharmAthene?
PharmAthene saw a decrease in short interest during the month of April. As of April 28th, there was short interest totalling 1,895,846 shares, a decrease of 24.8% from the April 13th total of 2,519,695 shares. Based on an average trading volume of 638,047 shares, the short-interest ratio is presently 3.0 days.
Who are some of PharmAthene's key competitors?
Some companies that are related to PharmAthene include HDFC Bank Limited (HDB), Berkshire Hathaway (BRK.B), Berkshire Hathaway (BRK-A), Berkshire Hathaway (BRK.A), JPMorgan Chase & Co. (JPM), Wells Fargo & Co (WFC), Bank of America Corp (BAC), Citigroup (C), HSBC Holdings plc (HSBC), Royal Bank of Canada (RY), Banco Santander, S.A. (SAN), China Life Insurance Co Ltd (LFC), Goldman Sachs Group (GS), BNP Paribas SA (BNPQY), Toronto-Dominion Bank (TD), Allianz SE (AZSEY), U.S. Bancorp (USB) and Mitsubishi UFJ Financial Group (MTU).
Who owns PharmAthene stock?
PharmAthene's stock is owned by a number of of institutional and retail investors. Top institutional investors include
NOVARTIS BIOVENTURES LTD
TRUFFLE CAPITAL S.A.S.
(10.10%). Company insiders that own PharmAthene stock include Eric I Richman and Prescott Group Capital Managem. View Institutional Ownership Trends for PharmAthene.
How do I buy PharmAthene stock?
Shares of PharmAthene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of PharmAthene stock cost?
One share of PharmAthene stock can currently be purchased for approximately $0.65.
Consensus Ratings for PharmAthene (NYSE:PIP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for PharmAthene (NYSE:PIP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for PharmAthene (NYSE:PIP)Earnings History by Quarter for PharmAthene (NYSE:PIP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2014||($0.03)||($0.07)||$3.50 million||$0.96 million||View||N/A|
Earnings Estimates for PharmAthene (NYSE:PIP)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS
Current Dividend Information for PharmAthene (NYSE:PIP)
|Most Recent Dividend:||2/3/2017|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||0.00% (Based on This Year's Estimates)|
0.00% (Based on Next Year's Estimates)
Dividend History by Quarter for PharmAthene (NYSE:PIP)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for PharmAthene (NYSE:PIP)Insider Trades by Quarter for PharmAthene (NYSE:PIP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/9/2016||Prescott Group Capital Managem||Major Shareholder||Sell||1,354,632||$3.26||$4,416,100.32|| |
|4/13/2016||Eric I Richman||Director||Sell||329,354||$2.20||$724,578.80|| |
|4/8/2016||Eric I Richman||Director||Sell||11,767||$2.20||$25,887.40|| |
|3/19/2015||Peter Steven St||Director||Buy||25,000||$1.65||$41,250.00|| |
|1/7/2015||Linda L Chang||CFO||Sell||29,600||$2.10||$62,160.00|| |
|9/22/2014||Prescott Group Capital Managem||Major Shareholder||Buy||15,000||$1.55||$23,250.00|| |
Headline Trends for PharmAthene (NYSE:PIP)
Latest Headlines for PharmAthene (NYSE:PIP)
|PharmAthene, Inc. (PIP) Sees Large Decrease in Short Interest|
www.americanbankingnews.com - May 10 at 7:00 AM
|Today's Research Reports on Biotech Stocks to Watch: AVEO Pharmaceuticals and PharmAthene|
finance.yahoo.com - May 5 at 8:41 AM
|PharmAthene (PIP) Earning Positive Media Coverage, Study Shows|
www.americanbankingnews.com - May 4 at 2:56 PM
|PharmAthene reports 1Q loss|
finance.yahoo.com - May 4 at 8:15 AM
|PharmAthene Reports First Quarter 2017 Financial and Operational Results - PR Newswire (press release)|
www.prnewswire.com - May 3 at 7:47 PM
|PharmAthene Reports First Quarter 2017 Financial and Operational Results|
finance.yahoo.com - May 3 at 7:47 PM
|PharmAthene (PIP) Earns Daily Media Sentiment Score of 0.21|
www.americanbankingnews.com - April 30 at 5:45 PM
|PharmAthene (PIP) Given News Impact Score of 0.01|
www.americanbankingnews.com - April 27 at 6:50 PM
|PharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT)|
www.streetinsider.com - April 26 at 11:06 PM
|PharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT) - StreetInsider.com|
www.streetinsider.com - April 26 at 6:02 PM
|PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market|
finance.yahoo.com - April 26 at 6:02 PM
|ETFs with exposure to PharmAthene, Inc. : April 19, 2017|
finance.yahoo.com - April 19 at 7:13 PM
|Somewhat Critical Media Coverage Somewhat Likely to Impact PharmAthene (PIP) Share Price|
www.americanbankingnews.com - April 17 at 5:01 PM
|PharmAthene (PIP) Given Daily News Impact Score of -0.10|
www.americanbankingnews.com - April 14 at 1:08 PM
|PharmAthene, Inc. (PIP) Sees Large Increase in Short Interest|
www.americanbankingnews.com - April 11 at 7:11 PM
|ETFs with exposure to PharmAthene, Inc. : April 7, 2017|
finance.yahoo.com - April 7 at 7:37 PM
|PHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - March 29 at 7:58 PM
|Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™|
finance.yahoo.com - March 28 at 9:44 AM
|PharmAthene, Inc. (PIP) Short Interest Update|
www.americanbankingnews.com - March 25 at 7:14 AM
|PHARMATHENE, INC Financials|
finance.yahoo.com - March 18 at 6:36 PM
|PharmAthene Reports Year-End 2016 Financial and Operational Results|
finance.yahoo.com - March 14 at 6:44 PM
|PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement|
biz.yahoo.com - March 14 at 6:44 PM
|PharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune|
finance.yahoo.com - March 13 at 9:46 AM
|PharmAthene, Inc. (PIP) Short Interest Down 56.8% in February|
www.americanbankingnews.com - March 9 at 6:30 PM
|Pepsico CFO: We have terrific momentum|
finance.yahoo.com - February 16 at 6:51 PM
|Pepsico CFO: Great business in Mexico|
finance.yahoo.com - February 16 at 6:51 PM
|Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix|
www.thestreet.com - February 7 at 9:03 PM
|Altimmune to Present at the BIO CEO & Investor Conference|
finance.yahoo.com - February 6 at 9:06 AM
|Form 425 PHARMATHENE, INC Filed by: PHARMATHENE, INC|
www.streetinsider.com - February 1 at 9:41 PM
|[$$] Gormley's Take: As IPO Market Tightens, Biotechs Find Another Route to Public Listing|
www.wsj.com - February 1 at 9:41 PM
|PharmAthene and Altimmune to Merge in All-Stock Deal|
www.investopedia.com - January 23 at 7:33 PM
|Two of region's anthrax-fighting companies announce merger|
us.rd.yahoo.com - January 20 at 8:05 PM
|PharmAthene (PIP), Altimmune to Merge in All-Stock Transaction - StreetInsider.com|
www.streetinsider.com - January 20 at 1:18 AM
|PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases|
finance.yahoo.com - January 20 at 1:18 AM
|6:32 am PharmAthene and privately-held Altimmune announce merger in an all-stock transaction|
finance.yahoo.com - January 20 at 1:17 AM
|PHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off|
biz.yahoo.com - January 20 at 1:17 AM
|Mid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike Higher|
feeds.benzinga.com - January 19 at 4:05 PM
PharmAthene (PIP) Chart for Sunday, May, 28, 2017